| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 827 | 2021 |
| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 169 | 2022 |
| Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer M Kohli, W Tan, T Zheng, A Wang, C Montesinos, C Wong, P Du, S Jia, ... EBioMedicine 54, 2020 | 107 | 2020 |
| Overall survival with [177Lu] Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase … MS Hofman, L Emmett, S Sandhu, A Iravani, JP Buteau, AM Joshua, ... The Lancet Oncology 25 (1), 99-107, 2024 | 83 | 2024 |
| Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multianalyte liquid biopsy assay for metastatic prostate cancer H Fettke, EM Kwan, MM Docanto, P Bukczynska, N Ng, LJK Graham, ... European urology 78 (2), 173-180, 2020 | 59 | 2020 |
| The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology GP Risbridger, AK Clark, LH Porter, R Toivanen, A Bakshi, NL Lister, ... Nature communications 12 (1), 5049, 2021 | 58 | 2021 |
| Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression E Lau, P McCoy, F Reeves, K Chow, M Clarkson, EM Kwan, K Packwood, ... Genome medicine 12, 1-11, 2020 | 52 | 2020 |
| Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial EM Kwan, L Spain, A Anton, CL Gan, L Garrett, D Chang, E Liow, ... European urology 81 (3), 253-262, 2022 | 48 | 2022 |
| Cell-free DNA in cancer: current insights H Fettke, EM Kwan, AA Azad Cellular Oncology 42, 13-28, 2019 | 48 | 2019 |
| Expression of androgen receptor splice variant 7 or 9 in whole blood does not predict response to androgen-axis–targeting agents in metastatic castration-resistant prostate cancer SQ To, EM Kwan, HC Fettke, A Mant, MM Docanto, L Martelotto, ... European urology 73 (6), 818-821, 2018 | 48 | 2018 |
| Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial K Fizazi, M Retz, DP Petrylak, JC Goh, J Perez-Gracia, L Lacombe, ... Journal for immunotherapy of cancer 10 (8), e004761, 2022 | 41 | 2022 |
| Tissue-and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: a systematic review K Van der Eecken, J Vanwelkenhuyzen, MP Deek, PT Tran, E Warner, ... European urology oncology 4 (6), 914-923, 2021 | 38 | 2021 |
| 177Lu-PSMA-617 and idronoxil in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): patient outcomes and predictors of treatment response in a phase I … S Pathmanandavel, M Crumbaker, AO Yam, A Nguyen, C Rofe, E Hovey, ... Journal of Nuclear Medicine 63 (4), 560-566, 2022 | 37 | 2022 |
| Phase I/II trial of the combination of 177lutetium prostate specific membrane antigen 617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate … M Crumbaker, S Pathmanandavel, AO Yam, A Nguyen, B Ho, L Chan, ... European urology oncology 4 (6), 963-970, 2021 | 37 | 2021 |
| Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase HM Lin, B Mak, N Yeung, K Huynh, TG Meikle, NA Mellett, EM Kwan, ... EBioMedicine 72, 2021 | 34 | 2021 |
| Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer NM Fonseca, C Maurice-Dror, C Herberts, W Tu, W Fan, AJ Murtha, ... Nature Communications 15 (1), 1828, 2024 | 33 | 2024 |
| Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer SH Tolmeijer, E Boerrigter, T Sumiyoshi, EM Kwan, SWS Ng, M Annala, ... Clinical Cancer Research 29 (15), 2835-2844, 2023 | 29 | 2023 |
| Plasma cell–free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer EM Kwan, C Dai, H Fettke, C Hauser, MM Docanto, P Bukczynska, N Ng, ... JCO Precision Oncology 5, 622-637, 2021 | 29 | 2021 |
| A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in … J Desai, B Markman, S Ananda, NC Tebbutt, M Michael, BJ Solomon, ... Journal of Clinical Oncology 35 (15_suppl), 3557-3557, 2017 | 28 | 2017 |
| Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the … B Tran, JM Ruiz‐Morales, E Gonzalez‐Billalabeitia, A Patrikidou, E Amir, ... Cancer medicine 9 (1), 116-124, 2020 | 26 | 2020 |